Literature DB >> 2464504

Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes.

J V Castell1, M J Gómez-Lechón, M David, T Andus, T Geiger, R Trullenque, R Fabra, P C Heinrich.   

Abstract

The three monokines interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF alpha), and interleukin-6 (IL-6) modulate acute phase plasma protein synthesis in adult human hepatocytes. Only IL-6 stimulates the synthesis of the full spectrum of acute phase proteins as seen in inflammatory states in humans, i.e. synthesis and secretion of C-reactive protein, serum amyloid A, fibrinogen, alpha 1-antitrypsin, alpha 1-antichymotrypsin and haptoglobin are increased while albumin, transferrin and fibronectin are decreased. IL-1 beta as well as TNF alpha, although having a moderate effect on the positive acute phase proteins and inhibiting the synthesis of fibrinogen, albumin and transferrin, fail to induce serum amyloid A and C-reactive protein. These data suggest that IL-6 plays the key role in the regulation of acute phase protein synthesis in human hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464504     DOI: 10.1016/0014-5793(89)80476-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  201 in total

1.  Interleukin-6 is necessary, but not sufficient, for induction of the humanC-reactive protein gene in vivo.

Authors:  B Weinhold; A Bader; V Poli; U Rüther
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

2.  Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes.

Authors:  Jian Yang; Chunshu Hao; Dongfang Yang; Deshi Shi; Xiulong Song; Xiaofei Luan; Gang Hu; Bingfang Yan
Journal:  Toxicol Lett       Date:  2010-06-09       Impact factor: 4.372

3.  Can serum interleukin-6 levels predict the outcome of patients with right iliac fossa pain?

Authors:  A T Goodwin; R I Swift; M J Bartlett; B S Fernando; S J Chadwick
Journal:  Ann R Coll Surg Engl       Date:  1997-03       Impact factor: 1.891

4.  The interleukin-6 promoter polymorphism is associated with elevated leukocyte, lymphocyte, and monocyte counts and reduced physical fitness in young healthy smokers.

Authors:  J R Ortlepp; J Metrikat; K Vesper; V Mevissen; F Schmitz; M Albrecht; P Maya-Pelzer; P Hanrath; C Weber; K Zerres; R Hoffmann
Journal:  J Mol Med (Berl)       Date:  2003-08-20       Impact factor: 4.599

5.  Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.

Authors:  S M Hsu; S S Xie; P L Hsu; J A Waldron
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

Review 6.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

7.  Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis.

Authors:  M C Cid; D S Grant; G S Hoffman; R Auerbach; A S Fauci; H K Kleinman
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Induction and suppression of cytokine release (tumour necrosis factor-alpha; interleukin-6, interleukin-1 beta) by Escherichia coli pathogenicity factors (adhesions, alpha-haemolysin).

Authors:  B König; W König
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

Review 9.  Managing cardiovascular risk in overweight children and adolescents.

Authors:  Sarita Dhuper; Sujatha Buddhe; Sunil Patel
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

10.  Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines.

Authors:  T D Quinn; H C Polk; M J Edwards
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.